Latest News - McKesson

Top Corporates Hub

McKesson

MCK | NYSE | United States
239
-18
Rank
$75.67B
Market Cap
$330.18B
+$ 28.68B
+9.51%
Revenue
$4.01B
+$ 1.47B
+57.87%
Earnings
43K
-8K
-15.69%
Employees
Can McKesson (MCK) Stay Cheap After A 338% Five Year Run?

11.07.2026 09:10

McKesson stock has delivered a very large 337.6% total return over the past 5 years, yet the latest valuation checks still suggest the shares lean cheap rather than stretched after that run. Over 5 years, McKesson’s 337.6% return points to a stock that has already rewarded investors heavily, so the key issue is whether today’s price still leaves room for further upside. Expectations around earnings growth supported by capital returns, including buybacks, can support today’s valuation, while...

Read More

McKesson (MCK) CEO Sells Shares As Company Names A New Strategy Chief

11.07.2026 02:10

McKesson (NYSE:MCK) disclosed a significant insider sale by its CEO, executed under a pre arranged trading plan. The company also announced the retirement of a key executive and the immediate appointment of a new Chief Strategy Officer. These management moves come alongside an updated company outlook and revised growth targets. McKesson is a major healthcare services and distribution company that connects drug manufacturers, pharmacies, providers, and payers across the supply chain. Insider...

Read More

McKesson Stock Is Shrinking, and That's The Point for Owners

09.07.2026 13:24

While the market debates growth, this healthcare giant is steadily retiring its own shares, a strategy that has quietly compounded value for investors.

Read More

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

06.07.2026 17:29

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Read More

Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?

06.07.2026 16:10

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More

Will Defensive Index Additions and TempraMed Deal Change McKesson's (MCK) Risk Perception Narrative

01.07.2026 00:15

In late June 2026, McKesson Corporation was added to several Russell 1000 defensive-style indexes and TempraMed announced an expanded North American distribution partnership with McKesson Medical-Surgical to broaden access to its temperature-controlled medication solutions. These developments highlight McKesson’s role as a key infrastructure provider in healthcare distribution while also reinforcing its positioning in indices focused on defensive characteristics. We’ll now examine how...

Read More

McKesson (MCK) Expands TempraMed Partnership Across North America For Full Portfolio Distribution

30.06.2026 14:06

TempraMed Technologies expanded its partnership with McKesson Medical-Surgical, a McKesson (NYSE:MCK) business, to distribute its full portfolio across North America. The agreement focuses on temperature-controlled medication solutions and is intended to strengthen McKesson’s B2B offering to healthcare providers. The expanded distribution supports TempraMed’s move toward a more diversified revenue model while using McKesson’s established medical-surgical network. For investors watching...

Read More

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

30.06.2026 07:05

Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer baseToronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio...

Read More

TCW Concentrated Large Cap Growth Fund Q1 2026 Portfolio Activity

24.06.2026 07:22

We believe McKesson's current share price does not adequately reflect the longer-term cash flow generation potential of the business.

Read More

McKesson Selects Moore, Oklahoma for a State-of-the-Art Regional Distribution Center Positions Cleveland County as a National Healthcare Supply Chain Hub

23.06.2026 19:41

Today, the Oklahoma Department of Commerce and the Cleveland County Economic Development Coalition announced that announced that McKesson Corporation, a Fortune 100, U.S. based company that serves as a logistical and operational backbone of the healthcare system to help ensure patients can access medicines, has selected Moore, Oklahoma as the location for a highly automated regional distribution facility at the North Moore Industrial Park. The new facility will replace an existing distribution c

Read More

McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies

23.06.2026 12:00

IRVING, Texas, June 23, 2026--Last week, McKesson Corporation hosted McKesson ideaShare 2026, the company’s annual event for independent community pharmacies, in Denver, Colorado.

Read More

CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?

19.06.2026 12:36

Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.

Read More

Is McKesson’s New US$2.25 Billion Term Loan Reshaping the Investment Case for MCK?

15.06.2026 07:14

Earlier in June 2026, McKesson amended its credit agreement to add a US$2.25 billion senior secured term B loan maturing in 2032, choosing a floating rate based on the Adjusted Term SOFR benchmark plus a margin to support liquidity and operational needs. This financing shift, coming soon after a revenue shortfall, an investment in the Medical-Surgical Solutions unit and increased CEO pay, highlights how capital structure, portfolio moves and governance decisions are all under close investor...

Read More

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

10.06.2026 13:00

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More

McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions

02.06.2026 12:00

IRVING, Texas, June 02, 2026--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo ("Apollo Funds") in McKesson’s Medical-Surgical Solutions ("MMS") business on June 1, 2026. This transaction represents a key milestone in McKesson’s intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth.

Read More

McKesson Announces Completion Of Previously-Announced $1.25B Minority Ownership Investment By Apollo Funds For 13% Of MCK Subsidiary Medical-Surgical Solutions

02.06.2026 08:14

Apollo Funds invested $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson

Read More

Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy

27.05.2026 11:00

Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product, MOGENRY™, subject to U.S. regulatory approval.

Read More

A Look Back at Healthcare Providers & Services Stocks’ Q1 Earnings: McKesson (NYSE:MCK) Vs The Rest Of The Pack

22.05.2026 19:08

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at McKesson (NYSE:MCK) and its peers.

Read More

Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

22.05.2026 16:16

McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.

Read More

TBRG Posts Q1 Earnings: How to Play the Stock Amid Pending Sell-off?

22.05.2026 14:13

TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.

Read More